Viewing Study NCT05199051


Ignite Creation Date: 2025-12-24 @ 11:51 PM
Ignite Modification Date: 2025-12-25 @ 9:46 PM
Study NCT ID: NCT05199051
Status: RECRUITING
Last Update Posted: 2025-02-19
First Post: 2021-11-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML
Sponsor: Centre Antoine Lacassagne
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module